0.0922
price up icon1.73%   0.0002
 
loading
Lyra Therapeutics Inc stock is traded at $0.0922, with a volume of 714.11K. It is up +1.73% in the last 24 hours and up +1.51% over the past month. Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$0.0924
Open:
$0.09
24h Volume:
714.11K
Relative Volume:
0.23
Market Cap:
$6.06M
Revenue:
$1.47M
Net Income/Loss:
$-97.61M
P/E Ratio:
-0.0619
EPS:
-1.49
Net Cash Flow:
$-80.90M
1W Performance:
-15.85%
1M Performance:
+1.51%
6M Performance:
-50.26%
1Y Performance:
-71.17%
1-Day Range:
Value
$0.088
$0.0968
1-Week Range:
Value
$0.0844
$0.1149
52-Week Range:
Value
$0.082
$0.344

Lyra Therapeutics Inc Stock (LYRA) Company Profile

Name
Name
Lyra Therapeutics Inc
Name
Phone
617-373-4600
Name
Address
480 ARSENAL WAY, WATERTOWN, MA
Name
Employee
30
Name
Twitter
@LyraTx
Name
Next Earnings Date
2025-03-12
Name
Latest SEC Filings
Name
LYRA's Discussions on Twitter

Compare LYRA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LYRA
Lyra Therapeutics Inc
0.0914 7.47M 1.47M -97.61M -80.90M -1.49
Biotechnology icon
ONC
Beigene Ltd Adr
242.08 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.23 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.31 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.27 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.13 5.92B 0 -153.72M -103.81M -2.00

Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades

Date Action Analyst Rating Change
May-07-24 Downgrade BofA Securities Buy → Underperform
May-07-24 Downgrade H.C. Wainwright Buy → Neutral
May-07-24 Downgrade Jefferies Buy → Hold
May-06-24 Downgrade William Blair Outperform → Mkt Perform
Oct-06-23 Resumed BTIG Research Buy
Aug-31-23 Initiated H.C. Wainwright Buy
May-24-22 Initiated Cantor Fitzgerald Overweight
May-26-20 Initiated BTIG Research Buy
May-26-20 Initiated BofA/Merrill Buy
May-26-20 Initiated Jefferies Buy
May-26-20 Initiated William Blair Outperform
View All

Lyra Therapeutics Inc Stock (LYRA) Latest News

pulisher
May 22, 2025

Petri Dish: Thermo Fisher’s new partner; Waters buys California company - The Business Journals

May 22, 2025
pulisher
May 20, 2025

Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews

May 20, 2025
pulisher
May 20, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

May 20, 2025
pulisher
May 20, 2025

US Stocks Likely To Open Lower After S&P 500's Six-Day Streak: 'Quick Recoveries Tend To See Stocks Rally More Over The Next 3-12 Months,' Says ExpertASP Isotopes (NASDAQ:ASPI) - Benzinga

May 20, 2025
pulisher
May 20, 2025

Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga

May 20, 2025
pulisher
May 19, 2025

Lyra Therapeutics Announces Reverse Stock Split Decision - TipRanks

May 19, 2025
pulisher
May 14, 2025

Lyra Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 14, 2025
pulisher
May 09, 2025

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 09, 2025
pulisher
May 08, 2025

JPMorgan Chase & Co. Has $32,000 Stake in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World

May 08, 2025
pulisher
May 08, 2025

JPMorgan Chase & Co. Has $40,000 Stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) - Defense World

May 08, 2025
pulisher
May 07, 2025

Lyra Therapeutics to Present 52-Week Extension Stage Results for Enlighten 1 Phase 3 Study for Lyr-210 for the Treatment of Chronic Rhinosinusitis At Cosm 2025 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times

May 07, 2025
pulisher
May 07, 2025

Lyra Therapeutics Reports Positive Safety and Efficacy Results for LYR-210 in Phase 3 Extension Study for Chronic Rhinosinusitis - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Lyra Therapeutics to Present 52-week Extension Stage - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Lyra Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView

May 07, 2025
pulisher
May 07, 2025

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewswire Inc.

May 07, 2025
pulisher
May 06, 2025

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Receives $1.25 Consensus Target Price from Analysts - Defense World

May 06, 2025
pulisher
May 06, 2025

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 06, 2025
pulisher
May 06, 2025

Lyra Therapeutics Nears Critical Phase 3 Results for Revolutionary CRS Treatment as Q1 Losses Narrow 62% - Stock Titan

May 06, 2025
pulisher
May 04, 2025

JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

May 04, 2025
pulisher
May 04, 2025

Geode Capital Management LLC Has $183,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World

May 04, 2025
pulisher
May 04, 2025

Ascendiant Capital Markets Predicts VMAR Q1 Earnings - Defense World

May 04, 2025
pulisher
Apr 30, 2025

Lyra Therapeutics Inc (LYRA) expanding its growth trajectory ahead - Sete News

Apr 30, 2025
pulisher
Apr 30, 2025

Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX

Apr 30, 2025
pulisher
Apr 29, 2025

Rhinitis Pipeline 2025: Groundbreaking Clinical Advancements - openPR.com

Apr 29, 2025
pulisher
Apr 29, 2025

Keeping an Eye on Lyra Therapeutics Inc (LYRA) After Insider Trading Activity - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

Lyra Therapeutics Inc (LYRA) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com

Apr 29, 2025
pulisher
Apr 29, 2025

What was Lyra Therapeutics Inc (LYRA)’s performance in the last session? - uspostnews.com

Apr 29, 2025
pulisher
Apr 29, 2025

Recent Insider Activity Could Benefit Schrodinger Inc (SDGR) - knoxdaily.com

Apr 29, 2025
pulisher
Apr 28, 2025

Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace

Apr 28, 2025
pulisher
Apr 28, 2025

Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Tuesday - The AM Reporter

Apr 28, 2025
pulisher
Apr 27, 2025

Lyra Therapeutics (LYRA) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News

Apr 27, 2025
pulisher
Apr 25, 2025

iCoreConnect Inc [ICCT] Shares Fall Approximately -87.86% Over the Year - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Lyra Therapeutics Inc [LYRA] Shares Rise 7.02 % on Thursday - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

QBTS Stock Sees Surge of Approximately 14.13% in Last Five Days - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Deckers Outdoor Corp [DECK] Records 200-Day SMA of $160.33 - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Shopify Inc [SHOP] Records 50-Day SMA of $99.94 - knoxdaily.com

Apr 25, 2025
pulisher
Apr 24, 2025

Analysts Say Lyra Therapeutics Inc (NASDAQ:LYRA) Can Really Get To 0.5 In 12 Months - Marketing Sentinel

Apr 24, 2025
pulisher
Apr 22, 2025

An Analysis of Lyra Therapeutics Inc (LYRA)’s Potential Price Growth - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Take off with Lyra Therapeutics Inc (LYRA): Get ready for trading - Sete News

Apr 22, 2025
pulisher
Apr 21, 2025

Is Lyra Therapeutics Inc (LYRA) worth investing in despite its undervalued state? - uspostnews.com

Apr 21, 2025
pulisher
Apr 11, 2025

Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $1.25 - Defense World

Apr 11, 2025
pulisher
Apr 08, 2025

Lyra Therapeutics stock hits 52-week low at $0.1 By Investing.com - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Lyra Therapeutics stock hits 52-week low at $0.1 - Investing.com

Apr 08, 2025
pulisher
Apr 03, 2025

TCBI Stock Sees Decline of Approximately -2.19% in Last Five Days - knoxdaily.com

Apr 03, 2025
pulisher
Apr 01, 2025

Technical analysis of Lyra Therapeutics Inc (LYRA) stock chart patterns - uspostnews.com

Apr 01, 2025
pulisher
Mar 31, 2025

Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 31, 2025
pulisher
Mar 28, 2025

Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline - Investing.com Australia

Mar 28, 2025
pulisher
Mar 27, 2025

PTCT Stock Sees Decline of Approximately -2.93% in Last Five Days - knoxdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Lyra Therapeutics Inc (LYRA) deserves deeper analysis - uspostnews.com

Mar 26, 2025

Lyra Therapeutics Inc Stock (LYRA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$286.89
price down icon 0.52%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
Cap:     |  Volume (24h):